It Might Be Years Before Impact Of Cyltezo Is Known

By John Wilkerson / October 21, 2021 at 9:49 AM

It will take time to determine the impact of the first interchangeable biosimilar for the autoimmune biologic Humira because a patent settlement will keep Humira biosimilars off the market until 2023 and because FDA is reviewing a citizen petition that could make a big difference in how much Cyltezo takes of Humira’s market, according to Ameet Sarpatwari, assistant professor of medicine at Harvard medical school.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.